Published in Drug Law Weekly, April 6th, 2004
Four-year findings from the first-in-man pilot study and 3-year findings from RAVEL, the clinical trial in Europe and Latin America, were presented at the American College of Cardiology 53rd annual scientific session.
Both studies were funded by Cordis Corp., a Johnson & Johnson company.
"The results of these two studies continue to demonstrate the long-term safety and efficacy of the CYPHER Stent," said Dennis Donohoe, MD, worldwide vice president of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.